2Greer N D. Voriconazole: the newest triazole antifungal agent [J]. Pro(Bayl Univ Med Cent) ,2003,16(2) :241-248.
3Herbrecht 1L, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N EnglJ Med, 2002, 347 (6) : 408-415.
4Vehreschild JJ, B6ohme A, Reichert D, et al. Treatment of invasive fungal infections in clinical practice : a multi-centre survey on customary dosing, treatment indications, effcacy and safeW of voriconazole. IntJ Hematol, 2008, 87 (2) : 126-131.
5Lev e que D, Nivoix Y, Jehl F, , et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents, 2006, 27 ( 4 ) : 274-284.
6Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis, 2008, 46 ( 2 ) : 201-211.
7Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis, 2004, 39 (8) : 1241-1244.
9Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica, 2001, 31 ( 1 ) : 1-10.
10Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin PharmacolTher, 2004, 75 (6): 587-588.
